Media stories about Penumbra (NYSE:PEN) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Penumbra earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.3528150376188 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
PEN has been the topic of several recent research reports. Canaccord Genuity restated a “buy” rating and issued a $113.00 price target on shares of Penumbra in a research report on Wednesday, January 24th. Zacks Investment Research upgraded Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. cut Penumbra from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, BMO Capital Markets boosted their target price on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $111.50.
Penumbra (NYSE:PEN) traded up $1.00 on Friday, hitting $90.30. The company had a trading volume of 296,479 shares, compared to its average volume of 231,853. The firm has a market cap of $3,064.69, a PE ratio of -410.45, a P/E/G ratio of 96.75 and a beta of 0.19. Penumbra has a 1-year low of $70.40 and a 1-year high of $116.35.
In related news, CEO Adam Elsesser sold 62,862 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $105.15, for a total value of $6,609,939.30. Following the sale, the chief executive officer now owns 1,191,887 shares of the company’s stock, valued at approximately $125,326,918.05. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Thomas Wilder sold 345 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $91.15, for a total value of $31,446.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 347,026 shares of company stock worth $35,271,762. Insiders own 13.50% of the company’s stock.
WARNING: This piece was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://ledgergazette.com/2018/02/12/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-penumbra-pen-stock-price.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.